Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
122.60
+0.09 (0.07%)
Oct 29, 2026, 4:00 PM EDT - Market closed

Kymera Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
102.2439.2147.0778.5946.8372.83
Revenue Growth
133.76%-16.70%-40.11%67.84%-35.71%114.00%
Gross Profit
-214.33-277.36-193.18-110.49-117.42-64.19
Operating Income
-404.89-345.54-256.71-165.53-161.26-100.53
Net Income
-349.43-311.35-223.86-146.96-154.81-100.22
Earnings Per Share
-3.63-3.69-2.98-2.52-2.87-2.09
EPS Growth
------

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
1,6461,619850.9436.32559.49567.61
Total Debt
76.682.2587.7684.6717.3417.96
Net Cash (Debt)
1,5691,537763.14351.64542.16549.64
Net Cash Growth
75.39%101.43%117.02%-35.14%-1.36%24.71%
Net Cash Per Share
16.2718.1910.176.0210.0511.45

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-287.57-232.89-194.5-102.83-153.09-128.95
Capital Expenditures
-1.33-1.45-12.84-34.48-2.84-1.6
Free Cash Flow
-288.89-234.34-207.34-137.31-155.92-130.54
Free Cash Flow Growth
------

Margins

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-209.65%---140.59%-250.76%-88.13%
Operating Margin
-396.04%-881.24%-545.36%-210.62%-344.37%-138.03%
Pretax Margin
-341.79%-794.04%-475.57%-186.99%-330.60%-137.60%
Profit Margin
-341.79%-794.04%-475.56%-186.99%-330.60%-137.60%
FCF Margin
-282.58%-597.64%-440.47%-174.71%-332.98%-179.24%

Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingOct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Forward PE
-34.2734.2734.2734.2734.27
PS Ratio
99.71158.7555.3517.9829.2544.75